Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.
about
Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infectionsEmerging drugs and vaccines for candidemiaCandida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsAdvances in the treatment of invasive neonatal candidiasis4′-O-substitutions determine selectivity of aminoglycoside antibioticsAntifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profileIn vitro antifungal activity of isavuconazole against Madurella mycetomatisIsavuconazole: A New Option for the Management of Invasive Fungal Infections.A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasisSafety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation studyPharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelActivity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.Coordinated roles of pregnane X receptor and constitutive androstane receptor in autoinduction of voriconazole metabolism in mice.In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Cladophialophora bantiana osteomyelitis in a renal transplant patient.Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.New generation azole antifungals in clinical investigation.Candida tropicalis in human disease.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.Profile of isavuconazole and its potential in the treatment of severe invasive fungal infectionsIsavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.Isavuconazonium: first global approval.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Targeting CYP51 for drug design by the contributions of molecular modeling.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Isavuconazole: a new extended spectrum triazole for invasive mold diseases.Isavuconazole therapy protects immunosuppressed mice from mucormycosis.Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.MIC values of voriconazole are predictive of treatment results in murine infections by Aspergillus terreus species complex.Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model.Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans.Efficacy of triazoles in a murine disseminated infection by Candida krusei.Experimental therapy with azoles against Candida guilliermondii.Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.
P2860
Q26744049-60A7C3B5-1315-412E-B696-0D9C946A124CQ26828993-26115DCA-61F6-46B7-ABF0-3B60D985E024Q26863344-98E952B9-2BB3-42F9-9D93-3CCB016CEC6DQ27022585-76DFD2BA-21A6-43AC-A3C0-7AE41CCEEE92Q27681495-40077010-3426-4A18-9109-3CD9CF129287Q28489096-34325F98-A88F-412F-90BA-541B972E4A7EQ34298778-0168C9B9-9C88-4956-A909-E6292172684DQ34474946-F46AB8BD-E039-4393-9846-FFE7BD412414Q35076974-E5C529FD-3F6E-4B71-A426-975D9FF70DA0Q35168889-7A736055-D1CF-4330-98EA-B863BE4E3DD6Q35385554-97BE2844-C104-46E5-A298-CF4B21722DB5Q36439061-FDB1C3D9-D016-4894-9B5D-A5D219A31056Q36667044-6F76F981-6132-4EC8-BB07-3B7B521E88EFQ37036173-E5AE1125-4F46-4F65-BF53-F9FB2ACE2896Q37096795-C5CD14CD-E462-453A-99FF-0C0436CFE109Q37199209-5C4CE87B-7860-411D-8B3C-19E8421A267EQ37203893-BEA44259-0F20-42E5-8789-635D93F9F768Q37579222-F73788C7-0855-4898-AECC-2EF4EE01F127Q37794979-78992C9C-D73C-4AA1-97F1-CD73FC432F0FQ37918556-D8D21423-5034-4A41-B434-002A88AC91AEQ38005226-5DE97D21-FA99-4399-8198-EBF06BB817B4Q38159688-882CB3A8-BB00-4824-8825-C30B2A06C17EQ38285488-2565EDD6-E905-425E-A665-42E763EBC574Q38436002-A7F1CD7E-6FE4-46F5-969B-6282B6285587Q38534865-466C7A78-7540-4C0A-93BC-0AE4C9516B8CQ38917135-EDB31D02-5513-41A8-A25A-9EE7E074D8E8Q38939506-284B2DBE-5776-4837-814F-901F476F06F6Q39003715-1ACABBAB-A459-4CFD-8FE4-552539F397F7Q39684037-14106FA4-3909-4D1C-90D3-ED8A8AFBFFFFQ41188300-8E27347A-D854-4B90-A704-9C1EDAD60020Q41453215-7DC35756-7C6D-4CA8-9182-7EA136A872B5Q41454252-071882F6-E154-4CCE-B3B0-2D8FCDF352B8Q41858290-2E695E88-77F8-4DC2-9505-12BD0D25728EQ42577834-A40325AB-1DD7-4A6B-A98A-86F8AAA149A9Q42657625-73E78583-6C75-40F9-B5D4-6C944D75D09DQ47151374-CE4E78AA-E710-4840-86C7-51C77DBED097
P2860
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Efficacy of isavuconazole, vor ...... tropicalis and Candida krusei.
@en
Efficacy of isavuconazole, vor ...... tropicalis and Candida krusei.
@nl
type
label
Efficacy of isavuconazole, vor ...... tropicalis and Candida krusei.
@en
Efficacy of isavuconazole, vor ...... tropicalis and Candida krusei.
@nl
prefLabel
Efficacy of isavuconazole, vor ...... tropicalis and Candida krusei.
@en
Efficacy of isavuconazole, vor ...... tropicalis and Candida krusei.
@nl
P2093
P2860
P356
P1476
Efficacy of isavuconazole, vor ...... tropicalis and Candida krusei.
@en
P2093
P2860
P304
P356
10.1093/JAC/DKN431
P407
P577
2008-11-13T00:00:00Z